Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up

Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up

Submitted by admin on March 29, 2019 - 10:02am
Source: 
Endpoints
News Tags: 
Amarin
Vascepa
FDA
M&A
Headline: 
Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up
snippet: 

Having unveiled an unexpected set of heart protective results for their fish oil-derived pill Vascepa, Amarin is marching ahead to fulfill blockbuster expectations for its cholesterol-lowering drug by submitting an application to expand Vascepa’s label to include the reduction in cardiovascular risk.

Do Not Allow Advertisers to Use My Personal information